---
title: "AEFI surveillance in Australia 2024: national report and vaccine signals"
id: "pubmed-43035019"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-43035019"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/43035019/"
doi: "10.33321/cdi.2026.50.046"
published_at: "2026-11-16T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# AEFI surveillance in Australia 2024: national report and vaccine signals
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-43035019
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/43035019/)
- **DOI:** [10.33321/cdi.2026.50.046](https://doi.org/10.33321%2Fcdi.2026.50.046)
- **Published At:** 2026-11-16T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The Therapeutic Goods Administration (TGA) received 6,232 reports of **AEFI** for vaccines administered in Australia during 2024. - This equates to an annual reporting rate of 22.9 per 100,000 population and 25.7 per 100,000 vaccine doses; rates rose slightly versus 2023. - Investigators reported the rate increase was likely associated with the rollout of the recombinant zoster vaccine (**RZV, Shingrix**) and expansion of the eligible zoster population. - **RZV (Shingrix)** had the highest number of AEFI reports in 2024, according to the authors. - The most frequently reported event categories included medication errors, hypersensitivity, nonspecific gastrointestinal symptoms, pyrexia, and injection site reactions. - Among vaccines newly introduced or updated in 2024, COVID-19 XBB.1.5 formulations (Comirnaty XBB.1.5 and Spikevax XBB.1.5) most commonly generated reports of medication errors and gastrointestinal symptoms. - For DTPa-HepB-IPV-Hib (Vaxelis) the study team observed hypersensitivity and pyrexia as the most commonly reported events. - Reports linked to the adjuvanted recombinant RSV vaccine (Arexvy) predominantly involved medication errors and exposure during pregnancy, investigators noted. - Fewer deaths were reported after vaccination in 2024 (28 reports) than in 2023 (34 reports); none of the 28 deaths indicated an emerging safety signal in the review. - The report describes continuous and annual analyses of spontaneous surveillance data; the abstract did not provide further methodological details such as case adjudication procedures or denominators by vaccine brand beyond rates per population and per doses.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/43035019/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43035019%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/43035019/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/43035019/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/43035019/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/43035019/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/43035019/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/43035019/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43035019%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43035019%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/43035019/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43035019/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43035019/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/43035019/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43035019/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/43035019/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/43035019/#abstract) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/43035019/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/43035019/#substances) Title & authors Abstract MeSH terms Substances Commun Dis Intell (2018) Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Commun+Dis+Intell+%282018%29%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Commun+Dis+Intell+%282018%29%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43035019/) . 2026 Nov 16:50. doi: 10.33321/cdi.2026.50.046. # Surveillance of adverse events following immunisation in Australia, 2024 [Thuy Nguyen](https://pubmed.ncbi.nlm.nih.gov/?term=Nguyen+T&cauthor_id=43035019)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43035019/#full-view-affiliation-1 "National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia; The University of Sydney Children's Hospital Westmead Clinical School, Westmead, New South Wales, Australia. thuy.nguyen8@health.nsw.gov.au."), [Nicholas Wood](https://pubmed.ncbi.nlm.nih.gov/?term=Wood+N&cauthor_id=43035019)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43035019/#full-view-affiliation-2 "National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia; The University of Sydney Children's Hospital Westmead Clinical School, Westmead, New South Wales, Australia."), [Kristine Macartney](https://pubmed.ncbi.nlm.nih.gov/?term=Macartney+K&cauthor_id=43035019)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43035019/#full-view-affiliation-2 "National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia; The University of Sydney Children's Hospital Westmead Clinical School, Westmead, New South Wales, Australia."), [Lucy Deng](https://pubmed.ncbi.nlm.nih.gov/?term=Deng+L&cauthor_id=43035019)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43035019/#full-view-affiliation-2 "National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia; The University of Sydney Children's Hospital Westmead Clinical School, Westmead, New South Wales, Australia.") Affiliations Expand ### Affiliations * 1 National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia; The University of Sydney Children's Hospital Westmead Clinical School, Westmead, New South Wales, Australia. thuy.nguyen8@health.nsw.gov.au. * 2 National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia; The University of Sydney Children's Hospital Westmead Clinical School, Westmead, New South Wales, Australia. * PMID: **43035019** * DOI: [ 10.33321/cdi.2026.50.046 ](https://doi.org/10.33321/cdi.2026.50.046) Item in Clipboard # Surveillance of adverse events following immunisation in Australia, 2024 Thuy Nguyen et al. Commun Dis Intell (2018). 2026. Show details Display options Display options Format Abstract PubMed PMID Commun Dis Intell (2018) Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Commun+Dis+Intell+%282018%29%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Commun+Dis+Intell+%282018%29%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43035019/) . 2026 Nov 16:50. doi: 10.33321/cdi.2026.50.046. ### Authors [Thuy Nguyen](https://pubmed.ncbi.nlm.nih.gov/?term=Nguyen+T&cauthor_id=43035019)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43035019/#short-view-affiliation-1 "National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia; The University of Sydney Children's Hospital Westmead Clinical School, Westmead, New South Wales, Australia. thuy.nguyen8@health.nsw.gov.au."), [Nicholas Wood](https://pubmed.ncbi.nlm.nih.gov/?term=Wood+N&cauthor_id=43035019)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43035019/#short-view-affiliation-2 "National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia; The University of Sydney Children's Hospital Westmead Clinical School, Westmead, New South Wales, Australia."), [Kristine Macartney](https://pubmed.ncbi.nlm.nih.gov/?term=Macartney+K&cauthor_id=43035019)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43035019/#short-view-affiliation-2 "National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia; The University of Sydney Children's Hospital Westmead Clinical School, Westmead, New South Wales, Australia."), [Lucy Deng](https://pubmed.ncbi.nlm.nih.gov/?term=Deng+L&cauthor_id=43035019)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43035019/#short-view-affiliation-2 "National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia; The University of Sydney Children's Hospital Westmead Clinical School, Westmead, New South Wales, Australia.") ### Affiliations * 1 National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia; The University of Sydney Children's Hospital Westmead Clinical School, Westmead, New South Wales, Australia. thuy.nguyen8@health.nsw.gov.au. * 2 National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia; The University of Sydney Children's Hospital Westmead Clinical School, Westmead, New South Wales, Australia. * PMID: **43035019** * DOI: [ 10.33321/cdi.2026.50.046 ](https://doi.org/10.33321/cdi.2026.50.046) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract This report summarises Australia's spontaneous surveillance data for adverse events following immunisation (AEFI) for all vaccines administered in 2024, reported to the Therapeutic Goods Administration (TGA). An adverse event(s) following immunisation is defined as any untoward medical occurrence which follows immunisation but does not necessarily have a causal relationship with use of the vaccine. Analyses of AEFI data are done continuously and also annually to detect new potential safety issues or changes to known safety issues. Overall, there were 6,232 AEFI reports for vaccines administered in 2024. This represents an annual AEFI reporting rate of 22.9 per 100,000 population and 25.7 per 100,000 vaccine doses, compared with 20.8 per 100,000 population and 24.1 per 100,000 doses in 2023. The slight increase in the AEFI reporting rates observed in 2024 was likely driven by the introduction of a new recombinant zoster vaccine (RZV, Shingrix) which replaced the live attenuated zoster vaccine (ZLV, Zostavax) on the National Immunisation Program (NIP) from November 2023, along with the expansion of the eligible population for zoster vaccination. In 2024, RZV (Shingrix) was associated with the highest number of reported AEFIs. The most frequently reported adverse events following immunisation were medication errors; hypersensitivity; gastrointestinal nonspecific symptoms; pyrexia; and injection site reaction. Among vaccines newly introduced in 2024, the most commonly reported adverse events were medication errors and nonspecific gastrointestinal symptoms for COVID-19 vaccines (Comirnaty XBB.1.5 and Spikevax XBB.1.5); hypersensitivity and pyrexia for the DTPa-HepB-IPV-Hib vaccine (Vaxelis); medication errors and exposure during pregnancy for the adjuvanted recombinant respiratory syncytial virus (RSV) pre-fusion F protein vaccine (Arexvy); and hypersensitivity and nonspecific gastrointestinal symptoms for RZV (Shingrix). Fewer deaths were reported following vaccination in 2024 (28 reports) than in 2023 (34 reports). None of the 28 reported deaths in 2024 indicated an emerging safety signal. **Keywords:** AEFI; adverse events; immunisation; surveillance; vaccine; vaccines. © Commonwealth of Australia CC BY-NC-ND. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## MeSH terms * Adverse Drug Reaction Reporting Systems* Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Adverse+Drug+Reaction+Reporting+Systems%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Adverse+Drug+Reaction+Reporting+Systems) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43035019/) * Australia / epidemiology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Australia%2Fepidemiology%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Australia) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43035019/) * Herpes Zoster Vaccine / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Herpes+Zoster+Vaccine%2Fadverse+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Herpes+Zoster+Vaccine) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43035019/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43035019/) * Immunization* / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Immunization%2Fadverse+effects%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Immunization) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43035019/) * Vaccination* / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Vaccination%2Fadverse+effects%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Vaccination) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43035019/) * Vaccines* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Vaccines%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Vaccines) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43035019/) * Vaccines* / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Vaccines%2Fadverse+effects%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Vaccines) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43035019/) ## Substances * Vaccines Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Vaccines%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Vaccines%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43035019/) * Herpes Zoster Vaccine Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Herpes+Zoster+Vaccine%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Herpes+Zoster+Vaccine%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43035019/) [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM **Send To** * [Clipboard](https://pubmed.ncbi.nlm.nih.gov/43035019/) * [Email](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43035019%2F%23open-email-panel) * [Save](https://pubmed.ncbi.nlm.nih.gov/43035019/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43035019%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43035019%2F%23open-collections-panel) * [Citation Manager](https://pubmed.ncbi.nlm.nih.gov/43035019/) [x] NCBI Literature Resources [MeSH](https://www.ncbi.nlm.nih.gov/mesh/) [PMC](https://www.ncbi.nlm.nih.gov/pmc/) [Bookshelf](https://www.ncbi.nlm.nih.gov/books) [Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited. Follow NCBI [ Twitter ](https://twitter.com/ncbi) [ Facebook ](https://www.facebook.com/ncbi.nlm) [ LinkedIn ](https://www.linkedin.com/company/ncbinlm) [ GitHub ](https://github.com/ncbi) [ ](https://ncbiinsights.ncbi.nlm.nih.gov/) [Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html) * [ Twitter ](https://twitter.com/NLM_NIH) * [ SM-Facebook ](https://www.facebook.com/nationallibraryofmedicine) * [ SM-Youtube ](https://www.youtube.com/user/NLMNIH) National Library of Medicine [8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323) [Web Policies](https://www.nlm.nih.gov/web_policies.html) [FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office) [HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html) [Help](https://support.nlm.nih.gov/?pagename=pubmed%3Apubmed%3Aabstract%3ANONE) [Accessibility](https://www.nlm.nih.gov/accessibility.html) [Careers](https://www.nlm.nih.gov/careers/careers.html) * [NLM](https://www.nlm.nih.gov/) * [NIH](https://www.nih.gov/) * [HHS](https://www.hhs.gov/) * [USA.gov](https://www.usa.gov/) ![](https://pubmed.ncbi.nlm.nih.gov/stat?HTTP_REFERER=&SELF_URL=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43035019%2F&browserheight=600&browserwidth=1080&colorDepth=24&connection_effectivetype=4g&connection_type=&cookieSize=637&cookieenabled=true&is_browser_supported=true&jsevent=render&jsloadtime=&jsperf_basePage=34&jsperf_connect=215&jsperf_dns=0&jsperf_navTimingNetworkMS=815&jsperf_navTimingRedirectCount=0&jsperf_navTimingType=navigate&jsperf_navType=0&jsperf_redirectCount=0&jsperf_ttfb=563&jsrendertime=&language_code=en-US&log_category=literature&log_displayeduids=43035019&log_op=retrieve&log_source_db=pubmed&myncbi_signed_in=false&ncbi_algorithm=&ncbi_app=pubmed&ncbi_cost_center=pubmed&ncbi_db=pubmed&ncbi_featured_srcdb=&ncbi_nwds=yes&ncbi_nwds_ver=1.2.5&ncbi_pcid=&ncbi_pdid=abstract&ncbi_phid=FC0700012F973C5500003759EF7D70B1.1.m_3&ncbi_program=&ncbi_timesinceload=5&ncbi_timesincenavstart=1208&ncbi_uid=43035019&pagename=pubmed%3Apubmed%3Aabstract%3ANONE&pinger_in_iframe=false&prev_phid=FC0700012F973C5500003D3CD1FB6724.1.m_3&screenavailheight=600&screenavailwidth=1080&scre
## Related Clinical Research

- [Big Pharma: AI halves early drug-discovery timelines; companies avoid Xinjiang trial sites](https://medichelpline.com/clinical-feed/stat-news-0-stat-pharmalittle-we-re-reading-about-sanofi-eyeing-insmed-ai-speeding-drug.md)
- [Hims and Noom bring experimental peptides to mainstream telehealth](https://medichelpline.com/clinical-feed/stat-news-1-stat-peptide-market-poised-to-explode-with-new-hims-and-noom-launches.md)
- [Real-World Safety of Nirmatrelvir Plus Ritonavir for COVID-19 in Japan: Post-Marketing Surveillance](https://medichelpline.com/clinical-feed/pubmed-41621946.md) (DOI: 10.7883/yoken.JJID.2024.380)
- [FDA Launches Global Reliance Disclosure Program to Enhance Access to Medicines](https://medichelpline.com/clinical-feed/fda-news-releases-0-fda-launches-the-global-reliance-disclosure-program-to-expand-patient-access-to.md)
- [COVID-19 Vaccination Disclosures on Twitter: Themes, Timing, and Public Engagement](https://medichelpline.com/clinical-feed/pubmed-43043654.md) (DOI: 10.2196/99837)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.